Clinical Trial: A Phase III Trial Evaluating Efficacy of LX101 for Inherited Retinal Dystrophy Associated With RPE65 Mutations

U.S., July 9 -- ClinicalTrials.gov registry received information related to the study (NCT07054632) titled 'A Phase III Trial Evaluating Efficacy of LX101 for Inherited Retinal Dystrophy Associated With RPE65 Mutations' on June 27.

Brief Summary: The purpose of the study is to evaluate the efficacy and safety of LX101 in subjects with biallelic RPE65 mutation-associated inherited retinal dystrophy. This is an open-label, multicenter, randomized controlled Phase III clinical trial. Subjects were randomly assigned in a 1:1 ratio to either the intervention group or the control group. Subjects in the intervention group received subretinal injection of LX101, while those in the control group received no treatment.

Study Start Date: Sept. 13, 2...